Prophylaxe der Migräne mit monoklonalen Antikörpern gegen CGRP oder den CGRP-Rezeptor: Ergänzung der Leitlinie 030/057 Therapie der Migräneattacke und Prophylaxe der Migräne

Hans-Christoph Diener (Editor), Arne May (Editor), Peer Carsten Tfelt-Hansen (Editor)


Monoclonal antibodies against the calcitonin gene-related peptide (CGRP) receptor (erenumab) or against CGRP (eptinezumab, fremanezumab, galcanezumab) are new substances for the preventive treatment of migraine. They represent an extension of the therapeutic options which already exist in migraine prevention. In registration studies, the efficacy and good tolerability of these specific substances have been demonstrated in patients with episodic and chronic migraine. The following treatment recommendation presents a summary of the pivotal studies. Recommendations are given for the targeted selection of patients as well as for the evaluation of therapeutic success and the duration of treatment. Finally, possible restrictions in the use of this new substance group are discussed.
Original languageGerman
PublisherDeutsche Gesellschaft fuer Neurologie - DGN
Number of pages62
Publication statusPublished - 2019

Cite this